•  
  •  
  •  
  •  

2025-08-31 16:17:32

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Titan unveils 8 new brand outlets across Delhi NCR, strengthening their retail footprint with 1000+ stores in FY26
  • Zigly Unveils New Experience Centre at Phoenix Marketcity, Strengthens Mumbai Presence
  • XTGlobal Infotech Ltd and ICICI Bank Ltd enter into loan agreement
  • NCC Limited receives orders worth Rs. 788.34 crore
  • Thomas Cook India & SOTC Travel ink long-term strategic MOU with Queensland Tourism

Keywords Selected:  AurobindoPharma

Research

  • Aurobindo Pharma - Entry into India - a little too late?

Stock Report

  • Apitoria Pharma Pvt Ltd receives 5 observations from USFDA for API facility
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Aurobindo Pharma Ltd to invest in Swarnaakshu Solar Power Pvt Ltd, purchase captive solar power
  • Lyfius Pharma Pvt Ltd restarts operations at Penicillin-G manufacturing facility
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Eugia Pharma receives USFDA Approval for Dasatinib Tablets
  • Aurobindo Pharma receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg
  • Aurolife Pharma LLC gets 11 observations from USFDA for Raleigh Plant
  • CuraTeQ Biologics completes a successful Phase 1 Pharmacokinetics study of Denosumab BP16, a proposed biosimilar to Prolia® and Xgeva®
  • CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
  • Apitoria Pharma Pvt Ltd's API manufacturing facility classified as VAI by USFDA
  • Auro Vaccines Pvt Ltd terminates license agreement with Hilleman Laboratories Singapore Pte Ltd
  • USFDA classifies Aurobindo Pharma Inc's warehouse as OAI
  • CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
  • US FDA completes inspection at Unit V of Apitoria Pharma Private Limited
  • CuraTeQ Biologics receives positive opinion for biosimilar Zefylti
  • Eugia Pharma receives USFDA Approval for Pazopanib Tablets, 200 mg
  • Aurobindo Pharma receives USFDA Approval for Cephalexin Tablets USP, 250 mg and 500 mg
  • Apitoria Pharma Pvt Ltd gets Form 483 with 10 observations from US FDA
  • Aurobindo Pharma Ltd to acquire balance 49% stake in GLS Pharma Ltd
  • Eugia Steriles Pvt Ltd receives EIR from USFDA for new injectable facility
  • LIC reduces stake in Aurobindo Pharma Ltd
  • Eugia Steriles Pvt Ltd receives 1st production approval from USFDA from new injectable facility
  • Agile Pharma BV acquires Ace Laboratories Ltd, UK

Latest Post

  • Titan unveils 8 new brand outlets across Delhi NCR, strengthening their retail footprint with 1000+ stores in FY26
  • Zigly Unveils New Experience Centre at Phoenix Marketcity, Strengthens Mumbai Presence
  • XTGlobal Infotech Ltd and ICICI Bank Ltd enter into loan agreement
  • NCC Limited receives orders worth Rs. 788.34 crore
  • Thomas Cook India & SOTC Travel ink long-term strategic MOU with Queensland Tourism


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024